EUVIMEDOpdag EUVIMED
Crossref

Increased Throughput of Combined Stability Testing and Metabolite Identification Using a Sample Multiplexing Strategy for the Optimization of Engineered Cyclic Peptide Drugs

Congliang Sun iD, Mark T Cancilla, Bahanu Habulihaz, Lisa A Vasicek iD, Daniel S Spellman iD, Sven Hackbusch, Sebastien Morin

Journal of the American Society for Mass Spectrometry · 2025

DOI: 10.1021/jasms.5c00113 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2025. Written by Congliang Sun and 6 co-authors. Institution: Merck & Co., Inc., West Point, Pennsylvania 19486, United States. Major MEDLINE topics: Peptides, Cyclic, Mass Spectrometry, High-Throughput Screening Assays. Cited 3 times so far (Crossref); 7 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Engineered cyclic peptides (ECPs) have been in the spotlight as novel drug modalities for challenging therapeutic targets. Oral delivery of engineered cyclic peptides benefits from ease of administration. However, one of the main hurdles in developing orally effective peptide drugs is their potential metabolic instability due to enzymatic degradation. To that end, in vitro experiments with simulated intestinal fluid (SIF) have been used to assess drug metabolic stability in the gastrointestinal tract. Currently, metabolic stability evaluations and biotransformation assessments are performed separately, which can be time-consuming and result in complex data analysis. Presented here is a sample multiplexing strategy to address these challenges by leveraging a Thermo Scientific Orbitrap Astral mass spectrometer with two complementary analyzers, enabling the simultaneous analysis of metabolic stability from the Orbitrap full scan and biotransformation from the Astral analyzer from one sample injection. Furthermore, we demonstrate that 10 engineered cyclic peptides can be pooled into one sample injection without compromising the data quality to decrease the instrument run time and improve the throughput of the assay.

Subjects

MeSH terms (MEDLINE)

Peptides, CyclicMass SpectrometryHigh-Throughput Screening AssaysDrug StabilityProtein EngineeringBiotransformationHumans

Substances

Peptides, Cyclic

Authors and institutions

  • Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Thermo Fisher Scientific, San Jose, California 95134, United States.
  • Thermo Fisher Scientific, Mississauga, Ontario L5N 5V4, Canada.

ORCID profiles: Congliang Sun, Lisa A Vasicek, Daniel S Spellman

Cite

APA

Sun, C., Cancilla, M. T., Habulihaz, B., Vasicek, L. A., Spellman, D. S., Hackbusch, S., & Morin, S. (2025). Increased Throughput of Combined Stability Testing and Metabolite Identification Using a Sample Multiplexing Strategy for the Optimization of Engineered Cyclic Peptide Drugs. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.5c00113

Vancouver

Sun C, Cancilla MT, Habulihaz B, Vasicek LA, Spellman DS, Hackbusch S, et al. Increased Throughput of Combined Stability Testing and Metabolite Identification Using a Sample Multiplexing Strategy for the Optimization of Engineered Cyclic Peptide Drugs. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.5c00113

BibTeX
@article{Sun2025,
  author = {Sun, Congliang and Cancilla, Mark T and Habulihaz, Bahanu and Vasicek, Lisa A and Spellman, Daniel S and Hackbusch, Sven and Morin, Sebastien},
  title = {Increased Throughput of Combined Stability Testing and Metabolite Identification Using a Sample Multiplexing Strategy for the Optimization of Engineered Cyclic Peptide Drugs},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2025},
  doi = {10.1021/jasms.5c00113}
}
Start for free →